The treatment of the posterior-segment ocular diseases, such as age-related eye diseases
(AMD) or diabetic retinopathy (DR), present a challenge for ophthalmologists due to the …

Background: Despite the success of anti-vascular endothelial growth factors (anti-VEGFs),
currently, there is a need for highly effective compounds that can alleviate the burden of …

Age-related macular degeneration (AMD) is the most common cause of legal blindness in
developed countries. Neovascular (ie, wet) AMD is currently managed with intravitreal …

Neovascular age-related macular degeneration (nAMD) is the leading cause of blindness in
the developed world. Current therapy includes monthly intraocular injections of anti-VEGF …

Extensive research is currently being conducted into novel ocular drug delivery systems
(ODDS) that are capable of surpassing the limitations associated with conventional …

Aberrant growth of blood vessels (neovascularization) is a key feature of severe eye
diseases that can cause legal blindness, including neovascular age-related macular …

Patients with wet age-related macular degeneration (AMD) require intravitreal injections of
bevacizumab (Bev) or other drugs, often on a monthly basis, which is a burden on the …

Purpose: Intravitreal administration of drug molecules is one of the most common routes for
treating posterior segment eye diseases. However, the properties of vitreous humour …

Purpose To evaluate longitudinally the performance of the Notal Vision Home OCT (NVHO),
comprising a spectral-domain OCT device for patient self-imaging at home, telemedicine …

Importance SB11 and reference ranibizumab (RBZ) are monoclonal anti–vascular
endothelial growth factor (VEGF)–A antibodies approved for the treatment of neovascular …